Wechselwirkungen · Zelboraf
Zelboraf 240 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 8
HOS-215542 · Präparat HOS-155464
Concomitant use of vemurafenib with agents metabolized by CYP1A2 with narrow therapeutic windows (e.g. agomelatine, alosetron, duloxetine, melatonin, ramelteon, tacrine, tizanidine, theophylline) is not recommended. If co-administration cannot be avoided, exercise caution, as vemurafenib may increase plasma exposure of CYP1A2 substrate drugs. Dose reduction of the concomitant CYP1A2 substrate drug may be considered, if clinically indicated. Co-administration of vemurafenib increased the plasma exposure (AUC) of caffeine (CYP1A2 substrate) 2.6-fold. In another clinical trial, vemurafenib increased Cmax and AUC of a single 2 mg dose of tizanidine (CYP1A2 substrate) approximately 2.2-fold and 4.7-fold, respectively.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ramelteon (HOS-215544) duloxetine (HOS-089666) tizanidine (HOS-089668) caffeine (HOS-085902) theophylline (HOS-085910) tacrine (HOS-215545) alosetron (HOS-089667) melatonin (HOS-115812)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-19T10:15:00Z · SHA-256 2d456fa760308f0a3cd38ceefcce188400597f529dcb630f5163ed6664af53db · Passage 104336a35985ee8240d457969e8e908d564dd5309cc8d70608eb01b3fb5fe95c · Zeichen 220–942 im Abschnitt